Journal
CHEMISTRYOPEN
Volume 1, Issue 4, Pages 177-183Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/open.201200014
Keywords
F-18-trans-cyclooctene; cancer; diabetes; exendin-4; insulinoma; positron emission tomography
Categories
Funding
- National Institutes of Health (NIH) [P01 AI54904, U24 CA092782, K01 1KO1K093766-01]
- German Academy of Sciences [2009-24]
Ask authors/readers for more resources
A number of exendin derivatives have been developed to target glucagon-like peptide 1 (GLP-1) receptors on beta cells in vivo. Modifications of exendin analogues have been shown to have significant effects on pharmacokinetics and, as such, have been used to develop a variety of therapeutic compounds. Here, we show that an exendin-4, modified at position 12 with a cysteine conjugated to a tetrazine, can be labeled with F-18-trans-cyclooctene and converted into a PET imaging agent at high yields and with good selectivity. The agent accumulates in beta cells in vivo and has sufficiently high accumulation in mouse models of insulinomas to enable in vivo imaging.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available